Evolution Biotechnologies founder Dr. David Harper interviewed for the financial website SeekingAlpha
Evolution Biotechnologies announces filing of its first patent application relating to the development of biological controls for the house dust mite
Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company established to expand the use of biological control into medically important areas, today announced the filing of UK patent application GB1513981.9, “Acaricides”, relating to its planned development of biological controls for the house dust mite. The application includes exemplification from the successful feasibility study previously carried out under the direction of Evolution’s Chief Officer, Dr. David Harper.
“This is an important step forward for the company, with claims detailing our initial targets and including important exemplification of the approaches to be taken in this work. It is intended to add additional exemplification during the priority year, building on the current position and developing this promising technology” said Dr. Harper.
About Evolution Biotechnologies
Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both significant unmet need and high market potential. The first stage of Evolution’s work will be based on the outcomes of a successful feasibility study on biological control of the house dust mite. The potential for developing a biological control for the bed bug will also be evaluated, along with the potential for additional targets.
About biological control
Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural sector and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date.
This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
Colworth Science Park
Tel UK: +44 (0) 1234 818312
Tel US: + 1 (0) 512 599 9979
- Evolution Biotechnologies listed by OBN Ventures20th July 2020 - 1:11 am
- Evolution Biotechnologies receives advance assurance for EIS status in the United Kingdom8th June 2020 - 5:58 am
- Evolution Biotechnologies is Working with Panda New Capital of Beijing to Access funding from the UK Government’s Future Fund23rd May 2020 - 5:55 am
Registered England No. 09473027
VAT Registration No. 233 3070 48